SillaJen Conducts 130 Billion KRW Paid-in Capital Increase: "Proactive Measure to Expand R&D"

Shinilajen announced on the 25th that it will conduct a paid-in capital increase worth 130 billion KRW. The primary purpose of the capital raising is investment in research and development. The company stated, "The ongoing pipeline development process is progressing successfully," and explained that this is a "preemptive measure to expand it." The lead underwriter is KB Securities, with SK Securities, Hanyang Securities, and Ebest Investment & Securities as joint underwriters, proceeding via a standby underwriting method.

This capital raising was decided to enhance the company's value in the future and to smoothly and stably develop the pipeline. Through this, BAL0891, which officially entered clinical trials in the US and Korea last year, is pursuing combination therapy (paclitaxel, immune checkpoint inhibitors) and indication expansion (acute myeloid leukemia). Additionally, the SJ-600 series is progressing with the manufacturing of clinical trial drugs and non-clinical toxicity tests according to Good Laboratory Practice (GLP), establishing various foundational data for entering clinical trials or for license-out purposes.

A Shinilajen representative said, “Once this capital raising is completed, it is expected to favorably impact securing mid- to long-term financial stability of the company and negotiations with global partners such as Regeneron,” adding, “Since there is no financial borrowing, the raised capital will fully belong to the company.”

This content was produced with the assistance of AI translation services.